

ISSN Print: 2617-4693 ISSN Online: 2617-4707 IJABR 2017; 1(1): 47-57 www.biochemjournal.com Received: 12-01-2017 Accepted: 21-03-2017

Richard M Gitimu

 a) Department of Biochemistry, Microbiology and
 Biotechnology, School of Pure and Applied Sciences,
 Kenyatta University, P.O Box 43844 00100, Nairobi, Kenya
 b) Department of Laboratory
 Medicine, Taita Taveta
 University, P.O Box 635-80300
 Voi, Kenya

Joseph K Gikunju

Department of Medical Laboratory Sciences, Jomo Kenyatta University of Agriculture and Technology, P.O Box 62000-00100 Nairobi.

Stanley K Waithaka

Department of Medical laboratory Sciences, Mount Kenya University, P.O Box 342-01000 Thika, Kenya

Eliud NM Njagi

Department of Biochemistry, Microbiology and Biotechnology, School of Pure and Applied Sciences, Kenyatta University, P.O Box 43844 00100, Nairobi, Kenya.

Corresponding Author: Richard M Gitimu

a) Department of Biochemistry, Microbiology and Biotechnology, School of Pure and Applied Sciences, Kenyatta University, P.O Box 43844 00100, Nairobi, Kenya b) Department of Laboratory Medicine, Taita Taveta University, P.O Box 635-80300 Voi, Kenya

Thyroid profile reference limits and normal values for adult and geriatric population of Taita-taveta County, Kenya

Richard M Gitimu, Joseph K Gikunju, Stanley K Waithaka and Eliud NM Njagi

DOI: https://doi.org/10.33545/26174693.2017.v1.i1a.118

Abstract

Reference interval limits for thyronine (TSH), thyroxine (T4) and triiodothyronine (T3) for geriatrics of the world including those of geriatrics of Taita-Taveta County, Kenya are limited. The aim of this study was to develop the 95% reference interval limits for thyronine (TSH), total thyroxine (T4), and total triiodothyronine (T3) for adults and geriatrics of Taita-Taveta County, Kenya. Two hundred and forty four referent individual randomly recruited from the four sub-county of Taita Taveta (Mwatate, Wundanyi, Voi and Taveta) County, Kenya participated in this reference interval limits development study. These referents had no history of thyroid gland diseases, were not on medication for thyroid diseases, and medications that affect the hypothalamus-pituitary-thyroid gland axis. These referents were free from HIV/ AIDS, syphilis, hepatitis B and C, and pregnancy. The serum used for the measurement of thyronin (TSH), total tetraiodothyronine (thyroxine [T4]) and triiodothyronine (T3) was obtained from blood which had been drawn from the vein of the 244 referent participants between 7-10 am after 8 to 12 hours of fasting recruited between May 2015 and December 2017. TSH, T4 and T3 were measured on a quality controlled calibrated Chemwell Auto-Analyzer machine using the principle that combines an enzyme immunoassay sandwich method with a final fluorescent detection (enzyme linked fluorescent assay (ELFA)) at the Clinical Chemistry Laboratory, Taita-Taveta Sub County Hospital, Voi, Kenya. The reference interval limits for the measured analytes was based on the median and 2.5 percentile and 97.5 percentile. The developed reference interval limits for TSH, T4 and T3 were 0-6 mU/L, 2-15 nmol/L and 0-4 nmol/L, respectively. There were significant age and sex related differences in T4. The developed reference interval limits for TSH, T4 and T3 differed from those reported in reagents manufacturer kits and literature. This study has established age and gender dependent 95% reference intervals for TSH, T4 and T3 that differ from those reported in literature. Each clinical laboratory therefore needs to develop their own reference intervals using their local healthy population for these analytes for accurate diagnosis and effective medical care for patients suffering from thyroid gland related diseases.

Keywords: tetraiodothyronine, Taita-Taveta, Wundanyi

Introduction

Clinical chemistry reference interval is the interval between, and including, two reference limits; the lower 2.5 percent and upper 97.5 percent limits. Reference intervals for thyroid hormones are developed using a minimum of 120 healthy referent individuals selected on the basis of meeting a specific exclusion and inclusion criteria and covering 95% of the healthy referent individuals. If the referent individuals are stratified by age and sex, each age category require a minimum of 120 individuals for each gender (Horowitz *et al.*, 2010) ^[10]. Reference interval for thyroid stimulating hormone (TSH), total triiodothyronine (T3), free triiodothyronine (fT3), total thyroxine (T4), and free thyroxine (fT4) are biochemical markers that are commonly used for clinical diagnosis of thyroid function disorders. The thyroid function disorders include graves' disease, thyroid nodule (toxic autonomously functioning thyroid nodule or toxic multinodular goitre), thyroiditis, and excess iodine from some medicines which cause hyperthyroidism, and hashimoto's thyroiditis, iodine deficiency and non-functioning thyroid gland that cause hypothyroidism (Musa *et al.* 2018; Ali *et al.*, 2018) ^[16, 1].

Thyroid stimulating hormone is the most sensitive biomarker used for assessment of thyroid function diseases in addition to diagnosing subclinical hyperthyroidism and hypothyroidism, and detecting recurrence of thyroid tumors. The factors that influence the reference interval for thyroid stimulating hormone (TSH) and thyroid hormones (T4, T3) include age, sex (pregnancy), dietary habits (eating goitrogenic foods containing goitrogenic chemicals), health status, some medications (Amiodarone, lugol's solution, some cough syrups), environment, race, ethnicity, genetics, laboratory methods and reagents used for detection, and iodine nutritional status (Musa et al. 2018) [16]. About 2.2 billion people from 130 countries of the world (including Kenya) are at risk of developing iodine deficiency disorders (IDD), despite the introduction of IDD programs such as the use of iodized salt formula in mid 1970s (Musa et al. 2018) [16]. The reference interval commonly used to assess thyroid function tests for geriatric populations in African countries, including Kenya are those for the adult western (mainly from Europe and northern America) population from commercial assay manufacturers reagents test kits even though it is known that age affects the levels of thyroid hormones. These reference interval limits are therefore inappropriate for geriatric populations of Kenya. This is despite the International Federation of Clinical Chemistry recommending that each clinical medicine laboratory develops its own local reference intervals for analytes using the local geriatric population for accurate clinical diagnosis, treatment, and monitoring of the performance of therapeutic treatment regimen for thyroid hormone diseases (Horowitz et al., 2010) [10]. Further, different countries of the world have previously reported different age and sex specific reference interval limits for thyroid hormones (Biondi and Cooper, 2008) [4] which are mostly different. There are no age and sex specific reference interval limits for geriatric population of Kenya including that for Taita-Taveta County. The aim of this study therefore was to develop age and sex specific 95% reference interval limits for thyroid hormones for adult and geriatric population of Taita-Taveta County, Kenya and compare them with those previously reported in medical literature for other populations of the world.

Materials and Methods Study site

This study was carried out at Taita-Taveta Moi sub-district Hospital, Voi, Kenya between May 2015 and December 2017.

Study population

The study population involved 254 were recruited, of which 10 samples haemolysed, and 2 were HIV positive. The reminder of 244 voluntarily recruited healthy adults and geriatrics including 120 males and 124 females from Taita-Taveta County, Kenya were subjected to full analysis.

Study design

This was a cross-sectional prospective study design involving 244 referent individuals of 50-95 years randomly recruited from the four sub-counties (Mwatate, Wundanyi, Voi and Taveta) of Taita Taveta County, Kenya. These referents had no history of thyroid gland diseases, were not on medication for thyroid diseases, and medications that affect the hypothalamus-pituitary-thyroid gland axis. These referents were free from HIV/ AIDS, syphilis, hepatitis B and C, and pregnancy.

Blood collection and sample preparation

The serum used for the measurement of thyronin (TSH), tetraiodothyronine (thyroxine [T4]) triiodothyronine (T3) was obtained from blood which had been drawn from the vein of the 244 referent participatants between 7-10 am after 8 to 12 hours of fasting recruited between May 2015 and December 2017. The 5 millitres of blood drawn from each referent individual was with a syringe was transferred to a labeled plain vacutainer tube and allowed to clot. The tubes containing clotted blood were placed in cooll boxed and transported to the Laboratory for analysis where the specimen were centriguged at 3000 g for five minutes. Serum was separated and transfered into bar coded vials for identification purposes. These vial specimen were either immediately analysed for the levels of TSH, T4, and T3 or stored at -20°C to be analysed later. Analysis was carried out with a quality controlled calibrated Chemwell Auto-Analyzer machine whose working principle combines an enzyme immunoassay sandwich method with a final fluorescent detection (enzyme linked fluorescent assay (ELFA)).

Ethical Approval

This study was approved by Kenyatta University Ethical Committee Ref Number I84/31987/15/ NACOSTI Ref number 16/22096/14531, and Taita-Taveta County medical director.

Laboratory Analysis

TSH, T4 and T3 in the serum samples and the quality control material were measured on a quality controlled calibrated Chemwell Auto-Analyzer machine using the principle that combines an enzyme immunoassay sandwich method with a final fluorescent detection (enzyme linked fluorescent assay (ELFA)) at the Department of Clinical Chemistry, Taita-Taveta Moi sub-district Hospital, Voi, Kenya. Reference interval limits for each of the measured analytes was calculated as median and 2.5 percentile and 97.5 percentile.

Data management and Statistical Analysis

Results from the 244 healthy referents were exported from the excel spreadsheet to SPSS software where the descriptive statistics mean, variance, standard deviation, standard error of mean, median, mode, skewness, standard error of skewness, kurtosis, standard eorror of kurtosis, minimum, maximum, range, and 2.5 percentile and 97.5 percentile were genenerated. These wre used to define the normality of the dataset. Results were expressed as median and 2.5 percentile and 97.5 percentile as recommended by CLSI (2010). Comparison of statistical differences between the values of each of the measured biochemical analytes for males and females was carried out using Mann-Whitney U test. Comparison of statistical differences within and between the values of each of the measured analytes for each gender for the three age categories (50-60, 60-70, 70-95 years) was carried out using Kruskal-Wallis H test followed by Mann-Whitney U test with an adjusted significant ρ-value of less than 0.0167. Results were presented as tables.

Results

Results for quality control material for thyroid hormones

The results of quality control material for thyroid hormones are presented in Table 1. It is evident that these results were within the assigned quality control values indicating that the analytical process was performing within expectations. Therefore, the measured thyroid stimulating hormone (TSH) and total thyroid hormone values of the study participants are accurate and reliable.

Table 1: Results for quality control material for thyroid hormones

Analyte (unit)	Assign	ned QC	report	Study QC report		
Anaryte (unit)	Mean	SD	% CV	Mean	SD	% CV
TSH (mU/L)	4.2`	0.12	2.9	4.3	0.07	1.6
T3 (mU/L)	2.9	0.08	2.6	2.9	0.08	2.3
T4 (nmol/L)	12.9	0.31	2.4	12.8	0.30	2.5

Results of the normality statistics of thyroid hormones for adult and geriatric population of Taita-Taveta County, Kenya The results of the normality statistics of thyroid hormones for adult and geriatric population of Taita-Taveta County, Kenya are depicted in Table 1.2. For the whole sample of 244 combined male and female, separate 120 male and 124 female referents of 50-95 years, the degree of skewness of the measured analytes values is 77.78% (7/9), while the kurtosis level is 55.56% (5/9). For the age category 50-60 years, the skewness level of the measured analytes values for the combined 68 male and female, separate 32 male and 36 female referents is 100% (9/9) while the kurtosis level is 22.22% (2/9). The three measured analytes for referent males were normally distributed in addition to TSH and T4 of combined male and female, and separate female referents were normally distributed. For the age category 60-70 years, the level of skewness for the measured analytes values if 66.67% (6/9) while that for kurtosis is 55.56% (5/9). For age category 70-95 years, the level of kurtosis for the measured analytes values is 55.56% (5/9) while that for kurtosis is 44.44% (4/9).

Table 2: Results of the normality statistics of thyroid hormones for adult and geriatric population of Taita-Taveta County, Kenya

Parameter	Condon	Normality statistics for thyroid hormones						
≥50-95 years	Gender	N	TSH (mU/L)	T4 (nmol/L)	T3 (nmol/L)			
	M&F	244	2.16±1.72	5.91±3.64	1.73±0.87			
Mean	F	124	2.24±1.87	5.87±3.49	1.66±0.79			
	M	120	2.08±1.54	5.94±3.84	1.81±0.96			
	M&F	244	0.110	0.233	0.056			
SES	F	124	0.168	0.313	0.070			
	M	120	0.141	0.348	0.087			
	M&F	244	2 (0-6)	4 (2-15)	2 (0-4)			
Median	F	124	2 (0-6)	4 (3-15)	2 (0-3)			
	M	120	2 (0-5.97)	4 (1-15.98)	2 (0-5.95)			
	M&F	244	2	4	2			
Mode	F	124	2	4	2			
	M	120	2	4	2			
	M&F	244	1.716	3.643	0.874			
SD	F	124	1.871	3.485	0.785			
	M	120	1.543	3.814	0.955			
	M&F	244	2.944	13.271	0.764			
Variance	F	124	3.502	12.146	0.616			
	M	120	2.380	14.543	0.913			
	M&F	244	1.162	1.355	1.516			
Skewness	F	124	1.321	1.430	0.578			
	M	120	0.780	1.300	1.983			
	M&F	244	0.156	0.156	0.156			
SES	F	124	0.217	0.217	0.217			
	M	120	0.221	0.221	0.221			
	M&F	244	3.813	0.894	7.356			
Kurtosis	F	124	4.722	1.073	4.439			
	M	120	1.032	0.778	8.046			
	M&F	244	0.310	0.310	0.310			
SEK	F	124	0.413	0.413	0.423			
	M	120	0.438	0.438	0.438			
	M&F	244	12	17	6			
Range	F	124	12	15	5			
	M	120	8	17	6			
	M&F	244	0	0	0			
Minimum	F	124	0	1	0			
	M	120	0	0	0			
	M&F	244	12	17	6			
Maximum	F	124	12	16	5			
	M	120	8	17	6			
			Percentiles					
	M&F	244	0	2	0			
2.5	F	124	0	3	0			
	M	120	0	1	0			

	M&F	244	6	15	4
97.5	F	124	6	15	3
97.3	M	120	5.97	15.98	5.95
>50.60	Gender				
≥50-60 years		N	TSH (mU/L)	T4 (nmol/L)	T3 (mU/L)
3.6	M&F	68	2.09±1.69	6.47±4.04	1.69±0.78
Mean	F	36	2.25±1.84	6.06±4.09	1.67±0.93
	M	32	1.91±1.51	6.94±4.00	1.72±0.58
	M&F	68	0.205	0.490	0.094
SEM	F	36	0.307	0.682	0.154
	M	32	0.267	0.707	0.103
	M&F	68	2 (0-6.55)	4 (1.73-16.28)	2 (0-3.82)
Median	F	36	2 (0-3)	4 (1-9.5)	2 (0-2.03)
	M	32	2 (0-3)	5 (2-9.75)	2 (0-2.00)
	M&F	68	2	4	2
Mode	F	36	1	4	2
	M	32	0	4	2
	M&F	68	1.690	4.043	0.778
SD	F	36	1.842	4.043	0.926
SD					
	M	32	1.510	3.999	0.581
<u>.</u>	M&F	68	2.858	16.342	0.605
Variance	F	36	3.393	16.740	0.857
	M	32	2.281	15.996	0.338
	M&F	68	0.832	1.084	2.176
Skewness	F	36	1.120	1.286	2.796
	M	32	0.109	0.959	-0.956
	M&F	68	0.291	0.291	0.291
SES	F	36	0.393	0.393	0.393
SES .	M	32	0.414	0.414	0.414
	M&F	68	1.000	0.027	13.351
Kurtosis	F	36	1.430	0.596	13.499
Kurtosis					
	M	32	-1.061	-0.244	1.388
	M&F	68	0.574	0.574	0.574
SEK	F	36	0.768	0.768	0.768
	M	32	0.809	0.809	0.809
	M&F	68	8	16	6
Range	F	36	8	16	8
	M	32	5	14	3
	M&F	68	0	1	0
Minimum	F	36	0	1	0
	M	32	0	2	0
	M&F	68	8	17	6
Maximum	F	36	8	17	6
Witaxiiidiii	M	32	5	16	
	111	34			3
				10	3
İ	M 0-T2		Percentiles		
2.5	M&F	68	Percentiles 0	1.73	0
2.5	F	68	Percentiles 0 0	1.73	0
2.5	F M	68 36 32	Percentiles 0 0 0	1.73 1 2	0 0
	F M M&F	68 36 32 68	Percentiles 0 0 0 0 6.55	1.73 1 2 16.28	0 0 0 3.82
2.5 97.5	F M M&F F	68 36 32 68 36	Percentiles 0 0 0 0 6.55 3	1.73 1 2 16.28 9.50	0 0 0 3.82 2.03
97.5	F M M&F F M	68 36 32 68 36 32	Percentiles 0 0 0 0 6.55 3 3	1.73 1 2 16.28 9.50 9.75	0 0 0 3.82 2.03 2.00
	F M M&F F M Gender	68 36 32 68 36 36 32 N	Percentiles 0 0 0 6.55 3 TSH (mU/L)	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L)	0 0 0 3.82 2.03 2.00 T3 (mU/L)
97.5 ≥60-70 years	F M M&F F M	68 36 32 68 36 36 32 N	Percentiles 0 0 0 6.55 3 TSH (mU/L) 2.17±1.82	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60	0 0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79
97.5	F M M&F F M Gender M&F F	68 36 32 68 36 32 N 103 41	Percentiles 0 0 0 6.55 3 TSH (mU/L) 2.17±1.82 1.95±1.41	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L)	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65
97.5 ≥60-70 years	F M M&F F M Gender M&F	68 36 32 68 36 36 32 N	Percentiles 0 0 0 6.55 3 TSH (mU/L) 2.17±1.82	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60	0 0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79
97.5 ≥60-70 years	F M M&F F M Gender M&F F	68 36 32 68 36 32 N 103 41	Percentiles 0 0 0 6.55 3 TSH (mU/L) 2.17±1.82 1.95±1.41	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65
97.5 ≥60-70 years Mean	F M M&F F M Gender M&F F M GN&F	68 36 32 68 36 32 N 103 41 62 103	Percentiles 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078
97.5 ≥60-70 years	F M M&F F M Gender M&F F M M F F F F F F F F F F F F F F F	68 36 32 68 36 32 N 103 41 62 103 41	Percentiles 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180 0.221	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355 0.595	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078
97.5 ≥60-70 years Mean	F M M&F F M Gender M&F F M M F M M M&F F M M M&F	68 36 32 68 36 32 N 103 41 62 103 41 62	Percentiles 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180 0.221 0.260	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355 0.595 0.441	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078 0.102 0.111
97.5 ≥60-70 years Mean SEM	F M M&F F M Gender M&F F M M M&F F M M&F	68 36 32 68 36 32 N 103 41 62 103 41 62 103	Percentiles 0 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180 0.221 0.260 2 (0-6)	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355 0.595 0.441 4 (1-15.40)	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078 0.102 0.111 2 (0-4.40)
97.5 ≥60-70 years Mean	F	68 36 32 68 36 32 N 103 41 62 103 41 62 103 41	Percentiles 0 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180 0.221 0.260 2 (0-6) 2 (0-5)	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355 0.595 0.441 4 (1-15.40) 4 (0.05-15.95)	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078 0.102 0.111 2 (0-4.40) 2 (0.05-3.95)
97.5 ≥60-70 years Mean SEM	F	68 36 32 68 36 32 N 103 41 62 103 41 62 103 41 62	Percentiles 0 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180 0.221 0.260 2 (0-6) 2 (0-5) 2 (0-8.55)	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355 0.595 0.441 4 (1-15.40) 4 (0.05-15.95) 4 (2.15-15.43)	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078 0.102 0.111 2 (0-4.40) 2 (0.05-3.95)
97.5 ≥60-70 years Mean SEM Median	F	68 36 32 68 36 32 N 103 41 62 103 41 62 103 41 62 103	Percentiles 0 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180 0.221 0.260 2 (0-6) 2 (0-5) 2 (0-8.55)	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355 0.595 0.441 4 (1-15.40) 4 (0.05-15.95) 4 (2.15-15.43)	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078 0.102 0.111 2 (0-4.40) 2 (0.05-3.95) 2
97.5 ≥60-70 years Mean SEM	F	68 36 32 68 36 32 N 103 41 62 103 41 62 103 41 62 103 41	Percentiles 0 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180 0.221 0.260 2 (0-6) 2 (0-5) 2 (0-8.55) 2 2	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355 0.595 0.441 4 (1-15.40) 4 (0.05-15.95) 4 (2.15-15.43) 4	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078 0.102 0.111 2 (0-4.40) 2 (0.05-3.95) 2 (0-5)
97.5 ≥60-70 years Mean SEM Median	F	68 36 32 68 36 32 N 103 41 62 103 41 62 103 41 62 103 41 62	Percentiles 0 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180 0.221 0.260 2 (0-6) 2 (0-5) 2 (0-8.55) 2 2 2	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355 0.595 0.441 4 (1-15.40) 4 (0.05-15.95) 4 (2.15-15.43) 4 4	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078 0.102 0.111 2 (0-4.40) 2 (0.05-3.95) 2 (0-5)
97.5 ≥60-70 years Mean SEM Median Mode	F	68 36 32 68 36 32 N 103 41 62 103 41 62 103 41 62 103 41 62 103	Percentiles 0 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180 0.221 0.260 2 (0-6) 2 (0-5) 2 (0-8.55) 2 2 2 1.823	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355 0.595 0.441 4 (1-15.40) 4 (0.05-15.95) 4 (2.15-15.43) 4 4 3.599	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078 0.102 0.111 2 (0-4.40) 2 (0.05-3.95) 2 (0-5) 2 2 2
97.5 ≥60-70 years Mean SEM Median	F	68 36 32 68 36 32 N 103 41 62 103 41 62 103 41 62 103 41 62 103 41 62 103 41	Percentiles 0 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180 0.221 0.260 2 (0-6) 2 (0-5) 2 (0-8.55) 2 2 2	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355 0.595 0.441 4 (1-15.40) 4 (0.05-15.95) 4 (2.15-15.43) 4 4	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078 0.102 0.111 2 (0-4.40) 2 (0.05-3.95) 2 (0-5) 2 2 2 0.789 0.652
97.5 ≥60-70 years Mean SEM Median Mode	F	68 36 32 68 36 32 N 103 41 62 103 41 62 103 41 62 103 41 62 103	Percentiles 0 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180 0.221 0.260 2 (0-6) 2 (0-5) 2 (0-8.55) 2 2 2 1.823	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355 0.595 0.441 4 (1-15.40) 4 (0.05-15.95) 4 (2.15-15.43) 4 4 3.599	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078 0.102 0.111 2 (0-4.40) 2 (0.05-3.95) 2 (0-5) 2 2 2
97.5 ≥60-70 years Mean SEM Median Mode	F	68 36 32 68 36 32 N 103 41 62 103 41 62 103 41 62 103 41 62 103 41 62 103 41	Percentiles 0 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180 0.221 0.260 2 (0-6) 2 (0-5) 2 (0-8.55) 2 2 2 1.823 1.413	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355 0.595 0.441 4 (1-15.40) 4 (0.05-15.95) 4 (2.15-15.43) 4 4 3.599 3.809	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078 0.102 0.111 2 (0-4.40) 2 (0.05-3.95) 2 (0-5) 2 2 2 0.789 0.652
97.5 ≥60-70 years Mean SEM Median Mode	F	68 36 32 68 36 32 N 103 41 62 103 41 62 103 41 62 103 41 62 103 41 62	Percentiles 0 0 0 0 6.55 3 3 TSH (mU/L) 2.17±1.82 1.95±1.41 2.32±2.05 0.180 0.221 0.260 2 (0-6) 2 (0-5) 2 (0-8.55) 2 2 1.823 1.413 2.047	1.73 1 2 16.28 9.50 9.75 T4 (nmol/L) 5.83±3.60 5.54±3.81 6.02±3.47 0.355 0.595 0.441 4 (1-15.40) 4 (0.05-15.95) 4 (2.15-15.43) 4 4 3.599 3.809 3.471	0 0 3.82 2.03 2.00 T3 (mU/L) 1.75±0.79 1.78±0.65 1.73±0.87 0.078 0.102 0.111 2 (0-4.40) 2 (0.05-3.95) 2 (0-5) 2 2 2 0.789 0.652 0.872

	1	1 1	1.100	12.040	0.740
	M	62	4.189	12.049	0.760
	M&F	103	1.707	1.368	0.972
Skewness	F	41	0.258	1.570	0.250
	M	62	1.870	1.279	1.187
	M&F	103	0.238	0.238	0.238
SES	F	41	0.369	0.369	0.369
	M	62	0.304	0.304	0.304
	M&F	103	7.063	0.926	5.229
Wt:-	F	41	-0.616	1.580	3.225
Kurtosis					
	M	62	6.972	0.686	5.392
	M&F	103	0.472	0.472	0.472
SEK	F	41	0.724	0.724	0.724
	M	62	0.599	0.599	0.599
	M&F	103	12	16	5
Range	F	41	5	16	4
Tunge	M	62	12	15	5
	M&F	103	0	0	0
3.61			-	-	
Minimum	F	41	0	0	0
	M	62	0	1	0
	M&F	103	12	16	5
Maximum	F	41	5	16	4
	M	62	12	16	5
	111	02	Percentiles	10	J
	M&F	103	0	1	0
2.5	F	41	0	0.05	0.05
2.3					
	M	62	0	2.15	0
	M&F	103	6	15.40	4.40
97.5	F	41	5	15.95	3.95
	M	62	8.55	15.43	5
≥70-95 years	Gender	N	TSH (mU/L)	T4 (nmol/L)	T3 (mU/L)
	M&F	73	2.22±1.60	5.49±3.28	1.75±1.06
Mean	F	30	2.43±1.85	4.43±2.37	1.47±0.78
Mean		43		6.23±3.63	1.47±0.78 1.95±1.19
	M		2.07±1.40		
	M&F	73	0.187	0.384	0.125
SEM	F	30	0.338	0.435	0.142
	M	43	0.214	0.554	0.182
	M&F	73	2 (0-6)	4 (1.85-15.30)	2 (0-6)
Median	F	30	2.5 (0-4)	4 (3-5.4)	2 (0-2.2)
	M	43	2 (0-5.90)	4 (1.10-16.80)	2 (0-6)
	M&F	73	2 (0-3.50)	4 (1.10-10.00)	2 (0-0)
N. 1					
Mode	F	30	0	4	2
	M	43	2	4	2
	M&F	73	1.601	3.279	1.064
SD	F	30	1.851	2.373	0.776
	M	43	1.404	3.631	1.194
	M&F	73	2.562	10.753	1.133
Variance	F	30	3.426	5.633	0.602
v arrance	M		1.971	13.183	
		43			1.426
a.	M&F	73	0.424	1.690	1.509
Skewness	F	30	0.253	3.405	-0.593
	M	43	0.466	1.174	1.676
					0.281
	M&F	73	0.281	0.281	
SES					
SES	M&F F	30	0.427	0.427	0.427
SES	M&F F M	30 43	0.427 0.361	0.427 0.361	0.427 0.361
	M&F F M M&F	30 43 73	0.427 0.361 -0.306	0.427 0.361 2.491	0.427 0.361 5.784
SES Kurtosis	M&F F M M&F	30 43 73 30	0.427 0.361 -0.306 -0.906	0.427 0.361 2.491 13.724	0.427 0.361 5.784 -0.325
	M&F F M M&F F	30 43 73 30 43	0.427 0.361 -0.306 -0.906 0.380	0.427 0.361 2.491 13.724 0.864	0.427 0.361 5.784 -0.325 4.989
Kurtosis	M&F F M M&F F M M&F	30 43 73 30 43 73	0.427 0.361 -0.306 -0.906 0.380 0.555	0.427 0.361 2.491 13.724 0.864 0.555	0.427 0.361 5.784 -0.325 4.989 0.555
	M&F F M M&F F M M&F	30 43 73 30 43 73 30	0.427 0.361 -0.306 -0.906 0.380 0.555 0.833	0.427 0.361 2.491 13.724 0.864 0.555 0.833	0.427 0.361 5.784 -0.325 4.989 0.555 0.833
Kurtosis	M&F F M M&F F M M&F	30 43 73 30 43 73	0.427 0.361 -0.306 -0.906 0.380 0.555	0.427 0.361 2.491 13.724 0.864 0.555	0.427 0.361 5.784 -0.325 4.989 0.555
Kurtosis	M&F F M M&F F M M&F F	30 43 73 30 43 73 30 43	0.427 0.361 -0.306 -0.906 0.380 0.555 0.833 0.709	0.427 0.361 2.491 13.724 0.864 0.555 0.833 0.709	0.427 0.361 5.784 -0.325 4.989 0.555 0.833 0.709
Kurtosis SEK	M&F F M M&F F M M&F F M M&F	30 43 73 30 43 73 30 43 73	0.427 0.361 -0.306 -0.906 0.380 0.555 0.833 0.709 6	0.427 0.361 2.491 13.724 0.864 0.555 0.833 0.709 16	0.427 0.361 5.784 -0.325 4.989 0.555 0.833 0.709 6
Kurtosis	M&F F M M&F F M M&F F M M&F F	30 43 73 30 43 73 30 43 73 30	0.427 0.361 -0.306 -0.906 0.380 0.555 0.833 0.709 6	0.427 0.361 2.491 13.724 0.864 0.555 0.833 0.709 16 12	0.427 0.361 5.784 -0.325 4.989 0.555 0.833 0.709 6 3
Kurtosis SEK	M&F F M M&F F M M&F F M M&F F	30 43 73 30 43 73 30 43 73 30 43	0.427 0.361 -0.306 -0.906 0.380 0.555 0.833 0.709 6 6	0.427 0.361 2.491 13.724 0.864 0.555 0.833 0.709 16 12	0.427 0.361 5.784 -0.325 4.989 0.555 0.833 0.709 6 3 6
Kurtosis SEK Range	M&F F M M&F F M M&F F M M&F F M M&F	30 43 73 30 43 73 30 43 73 30 43 73	0.427 0.361 -0.306 -0.906 0.380 0.555 0.833 0.709 6 6 6	0.427 0.361 2.491 13.724 0.864 0.555 0.833 0.709 16 12 16	0.427 0.361 5.784 -0.325 4.989 0.555 0.833 0.709 6 3 6
Kurtosis SEK	M&F F M M&F F M M&F F M M&F F M M&F F	30 43 73 30 43 73 30 43 73 30 43 73 30	0.427 0.361 -0.306 -0.906 0.380 0.555 0.833 0.709 6 6 6 0	0.427 0.361 2.491 13.724 0.864 0.555 0.833 0.709 16 12 16 1	0.427 0.361 5.784 -0.325 4.989 0.555 0.833 0.709 6 3 6 0
Kurtosis SEK Range	M&F F M M&F	30 43 73 30 43 73 30 43 73 30 43 73	0.427 0.361 -0.306 -0.906 0.380 0.555 0.833 0.709 6 6 6	0.427 0.361 2.491 13.724 0.864 0.555 0.833 0.709 16 12 16 1 3	0.427 0.361 5.784 -0.325 4.989 0.555 0.833 0.709 6 3 6
Kurtosis SEK Range Minimum	M&F F M M&F	30 43 73 30 43 73 30 43 73 30 43 73 30 43 73 30 43	0.427 0.361 -0.306 -0.906 0.380 0.555 0.833 0.709 6 6 6 0	0.427 0.361 2.491 13.724 0.864 0.555 0.833 0.709 16 12 16 1	0.427 0.361 5.784 -0.325 4.989 0.555 0.833 0.709 6 3 6 0
Kurtosis SEK Range	M&F F M M&F F M M&F F M M&F F M M&F F	30 43 73 30 43 73 30 43 73 30 43 73 30	0.427 0.361 -0.306 -0.906 0.380 0.555 0.833 0.709 6 6 6 0	0.427 0.361 2.491 13.724 0.864 0.555 0.833 0.709 16 12 16 1 3	0.427 0.361 5.784 -0.325 4.989 0.555 0.833 0.709 6 3 6 0

	M	43	6	17	6					
Percentiles										
	M&F	73	0	1.85	0					
2.5	F	30	0	3	0					
	M	43	0	1.10	0					
	M&F	73	6	15.30	6					
97.5	F	30	4	5.4	2.2					
	M	43	5.90	16.80	6					

Reference interval limits for thyroid hormones for adults and geriatrics of Taita-Taveta County, Kenya

The established reference intervals for thyroid stimulating hormone (TSH), total triiodothyronine (T3), and total thyroxine (T4) for male population of Taita-Taveta County, Kenya was statistically similar to that of the female population of the same age range ($\rho > 0.05$). Therefore

combined reference interval limits of these parameters for this population were established. The established reference interval limits for thyroid hormones for adult and geriatric population of Taita-Taveta County, Kenya is 2 (0-6) mU/L for TSH, 2 (0-4) mU/L for T3, and 4 (2-15) nmol/L for T4 (Table 1.3).

Table 3: Reference interval limits for thyroid hormones for adults and geriatrics of Taita-Taveta County, Kenya

Amalysta (vmit)	Con	N	Median	Pero	centile			Difference	Difference between M&F	
Analyte (unit)	Sex	IN	Median	2.5 th	97.5 th	Reference interval	IV	Z value	Sig	
	M&F	244	2.16±1.72 2	0	6	0-6	6			
TSH (mU/L)	M	120	2.08±1.54 2	0	5.97	0-5.97	5.97	-0.519	$\rho = 0.604$	
	F	124	2.24±1.87 2	0	6	0-6	6			
	M&F	244	1.73±0.87 2	0	4	0-4	4			
T3 (mU/L)	M	120	1.81±0.96 2	0	5.95	0-5.95	5.95	-0.174	$\rho = 0.862$	
	F	124	1.66±0.79 2	0	3	0-3	3			
	M&F	244	5.19±3.64 4	2	15	2-15	13			
T4 (nmol/L)	M	120	5.94±3.84 4	1	15.98	1-15.98	14.98	-0.835	$\rho = 0.403$	
	F	124	5.87±3.49 4	3	15	3-15	12			

Results are expressed as Mean \pm standard deviation (SD) and Median and 95% range for the number of referent participants in the column labeled N. Statistical comparisons of the median values between male and female referent participants were carried out using Mann-Whitney U test. Differences were considered significant at $\rho < 0.05$

Effects of age on the reference interval for thyroid hormones for adult and geriatric population of Taita-Taveta County, Kenya

The effects of age on the reference interval limits for thyroid hormone for adult and geriatric population of Taita-Taveta County, Kenya are presented in Table 2. This effect was investigated by dividing the study population into three age categories as follows: (a) age category 1 (\geq 50-60 years), (b) age category 2 (\geq 60-70 years), (c) age category 3 (\geq 70-95 years). Reference interval limits differences between males and females were estimated within each age category using Mann-Whitney U test. Reference interval limits differences within and between the three age categories were carried out using Kruskal-Wallis H test followed by Mann-Whitney U test with Bonferroni correction where ρ -values less than 0.0167 were considered statistically significant.

Results indicate that using Kruskal-Wallis H test, the established reference interval limits for thyroid stimulating hormone (TSH) ($\chi^2(2) = 0.390$, $\rho = 0.823$), total thyroxine ($\chi^2(2) = 1.955$, $\rho = 0.376$) and total triiodothyronine (T3) ($\chi^2(2) = 449$, $\rho = 0.799$) for combined male and female adults and geriatrics of Taita-Taveta County, Kenya, were not significantly altered by advancement in age ($\rho > 0.05$) (Table 4). There was therefore no need for a follow-up

pairwise comparison using Mann-Whitney U test with adjusted significant ρ -value of 0.0167.

In addition results indicate that using Kruskal-Wallis H test, the established reference interval limits for thyroid stimulating hormone (TSH) ($\chi^2(2) = 1.137$, $\rho = 0.567$), and total triiodothyronine (T3) ($\chi^2(2) = 2.018$, $\rho = 0.365$) for female adults and geriatrics of Taita-Taveta County, Kenya were not significantly altered by advancement in age (Table 4). However, the reference interval limits for total thyroxine (T4) for female adults and geriatrics of Taita-Taveta County, Kenya were statistically significantly altered with advancement in age ($\chi^2(2) = 12.409$; $\rho = 0.002$). There was therefore need for a follow-up pairwise comparison using Mann-Whitney U test with adjusted significant ρ -value of 0.0167.

A follow-up pairwise comparison using Mann-Whitney U test indicates that the median reference interval limits for total thyroxine (T4) for female adults (5 (2-9.75) nmol/L) in the fifth decade with mean rank of 38.31 was statistically significantly higher than that of female geriatrics (4 (3-5.4) nmol/L) in the seventh decade onwards with mean rank of 24.23 (U = 262, z = -3.220, ρ = 0.001, r = 0.4089). However, this reference interval limit for total thyroxine (T4) for female adults in the fifth decade was statistically

similar to that of female geriatrics in sixth decade. Further, the median reference interval limits for total thyroxine (T4) for female geriatrics (4 (2.15-15.43) nmol/L) in the sixth decade with mean rank of 51.60 was statistically significantly higher than that of female geriatrics (4 (3-5.4) nmol/L) in the seventh decade onwards with mean rank of 35.97 (U = 614, z = -2.864, ρ = 0.004, r = 0.2986). Thus, the median reference interval limits for total thyroxine (T4) for female adults and geriatrics appear to be similar in the fifth and sixth decade but significantly drops from the seven decade onwards.

Results indicate that a Kruskal-Wallis H test for reference interval limits for thyroid stimulating hormone (TSH) ($\chi^2(2)$ = 0.161; ρ = 0.923), total thyroxine (T4) ($\chi^2(2)$ = 1.352; ρ = 0.509), and total triiodothyronine (T3) ($\chi^2(2)$ = 2.798; ρ =

0.247) for male adults and geriatrics of Taita-Taveta County, Kenya were not significantly affected by advancement in age ($\rho > 0.05$). There was therefore no need for a follow-up pairwise comparison using Mann-Whitney U test with adjusted significant ρ -value of 0.0167.

Further, an investigation on the effect of gender on the reference interval limits for thyroid hormones in specific age categories using Mann-Whitney U test indicates that the total thyroxine (T4) for male geriatrics (4 (1.1-16.8) nmol/L) in the seventh decade onwards with mean rank of 42.42 was statistically significantly higher than that for their female counterparts (4 (3-5.4) nmol/L) in the seventh decade onwards with mean rank of 29.23 (U = 412, z = -2.779, ρ = 0.005, r = 0.3253).

Table 4: Effects of age on the median reference interval for thyroid hormones for adult and geriatric population of Taita-Taveta County, Kenya

Analyte			Changes in thy	roid ho	ormone concentration	with	age		
(Units)	Sex	N	≥ 50-60 years	N	≥ 60-70 years	N	≥ 70-95 years	N	≥ 50-95 years
	M&F	68	2.09±1.69	103	2.17±1.82	73	2.22±1.60	244	2.16±1.72
			2 (0-6.55)		2 (0-6)		2 (0-6)		2 (0-6)
TSH	M	36	2.25±1.84	41	1.95±1.41	43	2.07±1.40	120	2.08±1.54
(mU/L)			2 (0-3)		2 (0-5)		2 (0-5.90)		2 (0-5.97)
	F	32	1.91±1.51	62	2.32±2.05	30	2.43±1.85	124	2.24±1.87
			2 (0-3)		2 (0-8.55)		2.5 (0-4)		2 (0-6)
	M&F	68	6.47±4.04	103	5.83±3.60	73	5.49±3.28	244	5.91±3.64
			4 (1.73-16.28)		4 (1-15.40)		4 (1.85-15.30)		4 (2-15)
T4	M	36	6.06±4.09	41	5.54±3.81	43	6.25±3.63	120	5.94±3.84
(nmol/L)			4 (1-9.50)		4 (0.05-15.95)		4 (1.1-16.80)↑*		4 (1-15.98)
	F	32	6.94 ± 4.00	62	6.02±3.47	30	4.43±2.37	124	5.87±3.49
			5 (2-9.75)		4 (2.15-15.43)		4 (3-5.4)↓ ^{bc}		4 (3-15)
	M&F	68	1.69±0.78	103	1.69±0.78	73	1.75±1.06	244	1.73±0.87
			2 (0-3.82)		2 (0-4.40)		2 (0-6)		2 (0-4)
Т3	M	36	1.67±0.93	41	1.78±0.65	43	1.95±1.19	120	1.81±0.96
(mU/L)			2 (0-2.03)		2 (0.05-3.95)		2 (0-6)		2 (0-5.95)
	F	32	1.72±0.58	62	1.73±0.87	30	1.47±0.78	124	1.66±0.79
			2 (0-2)		2 (0-5)		2 (0-2.2)		2 (0-3)

Results are expressed as mean \pm standard deviation (SD), and median and 95% range of the number of subjects indicated in the column labeled N. * ρ < 0.05 when male median reference interval limits are significantly different when compared to female median reference interval limits per each age category by Mann-Whitney U test; * $^{a}\rho$ < 0.0167 when median reference interval limits in age range \geq 50-60 years is significantly different when compared to median reference interval limits in age range \geq 50-60 years is significantly different when compared to median reference interval limits in age range \geq 50-60 years is significantly different when compared to median reference interval limits in age range \geq 70-95 years, and * $^{c}\rho$ < 0.0167 when median reference interval limits in age range \geq 60-70 years is significantly different when compared to median reference interval limits in age range \geq 70-95 years by Kruskal-Wallis H test followed by Mann-Whitney U test with Bonferroni corrections. Bracketed values are the median 2.5 and 97.5 percentiles for combined and separate gender in each of the three specific age categories.

Comparison of developed reference intervals for thyroid hormones for adult and geriatric population of Taita-Taveta County, Kenya with those reported in literature

A comparison of developed reference intervals for thyroid hormones for adult and geriatric population of Taita-Taveta County, Kenya with those reported in literature are presented in Table 1.5. These comparisons were performed by comparing the lower and upper reference interval limits of this study's reference intervals with those of other studies previously reported in medical literature.

Results indicate that for TSH, this study's gender independent lower reference interval limit is lower than that of Darfur (Sudan) (Ali *et al.*, 2018), British (Kratzsch *et al.*, 2005) ^[12], Australian (Hickman *et al.*, 2017) ^[8], American (Hollowell *et al.*, 20) ^[9], and Srpska Republic (Mirjani-Azaric *et al.*, 2017) ^[15] populations, and gender dependent upper reference interval limit for Khartoum (Sudan) (Musa *et al.*, 2018) ^[16] population. However, the gender independent upper reference interval limit for TSH in this

study is higher than that of gender independent upper reference interval limits for Darfur (Sudan) (Ali *et al.*, 2018), British (Kratzsch *et al.*, 2005) [12], Australian (Hickman *et al.*, 2017) [8], American (Hollowell *et al.*, 20) [9], and Srpska Republic (Mirjani-Azaric *et al.*, 2017) [15] populations, and gender dependent upper reference interval limit for Khartoum (Sudan) (Musa *et al.*, 2018) [16] population.

For T3, this study's gender independent lower reference interval limit is lower than that of gender dependent British (Kratzsch *et al.*, 2005) ^[12] population, and similar to that of Srpska Republic (Mirjani-Azaric *et al.*, 2017) ^[15] population, while the upper reference interval limit is higher than that of British (Kratzsch *et al.*, 2005) ^[12] population, and lower than that of the Srpska Republic (Mirjani-Azaric *et al.*, 2017) ^[15] population.

For T4, this study' gender independent lower and upper reference interval limits are lower than that of gender independent reference limits for American (Hollowell *et al.*,

2002) ^[9], Darfur (Sudan) (Ali *et al.*, 2018), and Srpska Republic (Mirjani-Azaric *et al.*, 2017) ^[15] populations, and gender dependent lower and upper reference interval limits for Khartoum (Sudan) (Musa *et al.*, 2018) ^[16], and British (Kratzsch *et al.*, 2005) ^[12] populations. Age dependent reference interval limits for TSH were reported by

Hollowell *et al.* (2002) ^[9] for the American population, and Ali *et al.* (2018) for western Sudan population (Table 1.5). Further, Ali *et al.* (2018) reported age dependent reference interval limits for T4 for western Sudan population (Table 1.6). These age dependent reference interval limits for TSH and T4 differ from those reported in this study.

Table 5: Effects of age on the median reference interval for thyroid hormones for adult and geriatric population of Taita-Taveta County, Kenya

Analyte (Unit)	Gender	This study RI	Hollowell <i>et al.</i> , 2002 [9]	Kratzsch <i>et al.</i> , 2005 [12]	Hickman <i>et al.</i> , 2017 [8]	Mirjani-Azaric <i>et al.</i> , 2017 [15]	Musa et al., 2018 [16]	Ali et al., 2018
TCII	M&F	0-6	0.45-4.12	0.40-3.77	0.43-3.28	0.65-5.39		0.05-3
TSH (mU/L)	M	0-5.97					0.5-3	
(IIIO/L)	F	0-6					0.5-3.4	
т2	M&F	0-4					0.8-2.7	0.8-2.8
T3 (mU/L)	M	0-5.95		1.23-2.97		0-4.61		
(IIIO/L)	F	0-3		1.28-2.33		0-4.97		
T4	M&F	2-15	66.9-165.9			73.01-127.7		72-161.1
(nmol/L)	M	1-15.98		71.4-166			63-165	
(IIIIOI/L)	F	3-15		68.4-125			62-148.2	

American population by Hollowell *et al.* (2002) ^[9], British population by Kratzsch *et al.* (2005) ^[12], Srpska Republic population by Mirjani-Azaric *et al.* (2017) ^[15], Australian population by Hickman *et al.* (2017) ^[8], Khartoum (Sudan) population by Musa *et al.* (2018) ^[16], Darfur (Sudan) population by Ali *et al.* (2018).

Table 6: Comparison of age related developed reference interval limits for thyroid hormones for adults and geriatrics of Taita-Taveta County, Kenya with those reported in medical literature

Analyte							
	This study RI		\geq 50-60 years	≥ 60-70 years	≥ 70-95	5 years	50-95 years
TSH		M&F					0-6
(mU/L)		M					
		F					
	Americans ^H		≥ 50-60 years	≥ 60-70 years	70-80 years	≥ 80 years	
		M&F	0.52-4.03	0.49-4.33	0.45-5.90	0.33-7.50	
		M	0.50-4.04	0.56-4.27	0.47-6.39	0.36-6.82	
		F	0.53-4.02	0.45-4.48	0.44-5.77	0.17-7.87	
	Germany ^V		50-79 years				
		M&F	0.19-2.09				
	Sudan ^A		51-60 years	≥ 60 years			
		M&F	0.5-2.6	0.2-2.5			
	Srpska		51-60 years	61-70 years			
	-	M&F	0-5.82	0-5.82			
T4	This study RI	M&F	2.38-15.63	2.38-15.63			2-15
(nmol/L)	-	M				1.1-16.8*	
		F				3.0-5.4bc	
	Sudan ^A		51-60 years	≥ 60 years			
		M&F	137-162	165-190.2			
	Srpska		51-60 years	61-70 years			
	-	M&F	0-286.04	0-286.04			
T3	This study RI	M&F					0-4
(mU/L)	-	M					
, ,		F					
	Sudan ^A		51-60 years	≥ 60 years			
		M&F	1-3	1-3.1			
	Srpska		51-60 years	61-70 years			
	•	M&F	0-1.49	0-1.49			
		M					
		F					

American population by Hollowell *et al.* (2002) ^[9], Western Pomerania, northeast of Germany population by Völzke *et al.* (2005) ^[22], Srpska Republic population by Mirjani-Azaric *et al.* 2017 ^[15], Nyala, Darfur region, western Sudan population by Ali *et al.* (2018).

Discussion, Conclusions and Recommendations

Results indicating that the thyroid stimulating hormone (TSH), total thyroxine (T4) and total triiodothyronine (T3) reference interval limits for the adult and geriatric male and female population of Taita-Taveta County, Kenya were

statistically similar implies that these parameters are gender independent. The developed age and gender independent reference intervals for thyroid hormones for both males and females of Taita-Taveta County, Kenya are 0-6 mU/L for TSH, 2-15 nmol/L for T4, and 0-4 mU/L for T3,

respectively. This study findings agrees with those of Hickman et al. (2017) [8] who reported gender and age independent reference intervals for TSH (0.43-3.28 mU/L). Wang et al. (2017) [23] also reported gender independent reference intervals for T4 of 73.48-138.93 nmol/L. Further. these results also agree with those reported by Kratzsch et al. (2005) [12] who reported gender independent reference interval for TSH of 1.36 (0.40-3.77) mU/L. However, these results contrast the gender dependent reference interval for total T4 with females (113 [71.4-166] nmol/L) having a significantly higher reference intervals than males (93.4 [68.4-125] nmol/L), and T3 with females (1.94 [1.23-2.97] mU/L) having a significantly higher reference intervals than males (1.72 [1.28-2.33] mU/L) reported by Kratzsch et al. (2005) [12]. These results are also in agreement with those reported by Mirjani-Azaric et al. (2017) [15] who reported gender independent reference interval limits for TSH of 0.75-5.32 mU/L, and T4 of 73.49-126.30 nmol/L and contrast the gender dependent reference interval limits for T3 with males (0-4.97 mU/L) having a significantly higher reference interval limits than females (0-4.61 mU/L). Wang et al. (2017) [23] reported gender dependent referenc interval limits for TSH of 0.66-4.95 mU/L for males and 0.72-5.84 mU/L for females with females having higher values than males, and T3 of 1.24-2.18 nmol/L for males and 1.20-2.10 nmol/L for females with males having higher values than females, respectively. Li et al. (2020) [13] reported gender dependent and age independent reference interval limits for TSH of 0.65-3.92 mU/L for males and 0.43-4.67 mU/L for females, T4 of 78.52-144.94 nmol/L for males and 64.49-145.20 nmol/L for females, and T3 of 1.17-2.04 nmol/L for males and 1.04-2.00 nmol/L for females with males having higher values tha females, respectively.

These results also differ from those reported by Gesing et al. (2012) [7] and Barbesino (2019) [2] who reported age dependence of thyroid hormone levels. Mirjani-Azaric et al. (2017) [15] also demonstrated that the reference interval of TSH decreased with advancement of age from age 20-30 years upto age 50 years after which its level reverts to that of age range 20-30 years and above 50 years. Musa et al. (2018) [16] reported gender dependent reference interval for TSH with males (1.7 [0.5-3.4] mU/L) having a significantly higher reference interval limits than females (1.1 [0.5-3.0] mU/L), T4 with females (106.0 [63-165] nmol/L) having a significantly higher reference interval limits than males (96.5 [62.0-148.2] nmol/L), and gender independent reference interval for total T3 of 1.4 (0.8-2.7) mU/L. Musa et al. (2018) [16] also demonstrated age dependent reference interval for T4 with increasing reference interval with advancement of age (for age range 20-30 years to above 60 years) and age independence of reference interval for TSH and T3. Ali et al. (2018) reported gender independent reference interval for TSH of 1.2 (0.50-3.0) mU/L, T4 of 111.0 (72.0-161.1) nmol/L and T3 of 1.5 (0.8-2.8) mU/L, respectively. Ali et al. (2018) also demonstrated age dependence reference interval for T4 and T3 with increasing reference interval with advancement of age. Völzke et al. (2005) [22] reported a gender independent reference interval for TSH of 0.25-2.12 mU/L. Völzke et al. (2005) [22] also demonstrated age dependence reference intervals for TSH with decreasing reference interval with advancement of age with age 20-49 years having a reference interval of 0.27-2.15 mU/L and age 50-79 years having a reference interval of 0.19-2.09 mU/L, respectively. Hollowell *et al.* (2002) [9] reported a gender independent reference interval for TSH of 1.39 (0.45-4.12) mU/L for the American population and a gender dependent reference interval for T4 with females (111.8 [66.9-165.9] nmol/L) having significantly higher reference interval than males (107.3 [64.4-156.0] nmol/L). Hollowell *et al.* (2002) [9] also demonstrated age dependent reference interval for TSH with advancement of age from 50-80 years (1.50 [0.52-4.03] mU/L for 50-59, 1.67 [0.49-4.33] mU/L for 60-69, 1.76 [0.45-5.90] mU/L for 70-79, and 1.90 [0.33-7.50] mU/L for above 80 years, respectively); T4 reference interval was demonstrated to decrease with advancement of age.

The decrease of T4 concentration with age especially in the seventh decade onwards in females but not in males could be associated with the observed corresponding increase in TSH concentration in females relative to its unchanging concentration in males resulting in overt hypothyroidism (Bensenor et al., 2012; Völzke et al., 2005) [3, 22] in females. This could be accounted for by the decrease in thyroid gland function with advancement with age especially in the females which is associated with hypothyroidism; that is, increased TSH levels and decreased T4 levels. For males, TSH levels are reported not to vary with aging as observed in this study population but increases with aging in females as observed in this study in the seventh decade onwards (Yeap et al., 2017) [24]. However, this increase in TSH levels in females with age is overcome by excluding females with antithyroid antibodies (Bensenor et al., 2012) [3]. The presence of both increased TSH levels and antithyroid antibodies is more common in females and increases with age. Elderly females have a higher prevalence of iodine deficiency than males and increased TSH levels is a sensitive biomarker of iodine deficiency in geriatrics (Bensenor *et al.*, 2012) [3].

The difference between the age independent thyroid function tests reference intervals developed in this study for the Taita-Taveta County population from the age and sex dependent thyroid function tests previously developed and reported from other parts of the world by other researchers could be due to: differences in ethnicity, iodine supply and hence iodine nutritional status of the referent individuals, the selection criteria used in defining the referent individuals, the principles and procedures of the detection methods used, and genetic factors.

The limitations of this study were: firstly, urinary iodine which would have been used to assess the association between the developed reference interval for thyroid hormones and iodine nutritional status was not measured. Secondly, the presence of thyroid antibodies, anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies which can result in higher than appropriate reference intervals of thyroid hormones were not assessed in this study. Thirdly, ultrasound was not used to assess the thyroid volume and thyroid enlargement to further confirm the healthy status of the selected referent population. The study used a health questionnaire, drug history, and clinical assessment to define thyroid disease free referent individuals which could result in including individuals with a developing thyroid disease resulting in higher than appropriate reference intervals; recall bias may affect results when using a questionnaire. Further, the health questionnaire and clinical assessment were used to remove other factors such as smoking and obesity which influence the reference intervals of thyroid hormones. Fourthly, this

study only developed reference intervals for total thyroxine (T4) and triiodothyronine (T3) without developing the reference intervals for free T4 and free T3 which are more sensitive indicators of iodine nutritional status as in other previously reported studies. Because samples were not collected at fixed times such as 08.00am to 12.00 noon, the developed reference intervals for thyroid hormones may be influenced by effects caused by circadian rhythm. The study involved a referent population of Taita-Taveta County and thus covered a narrow scope. A larger sample size of referent population including clinical laboratories of the eight counties of Kenya is needed to generate national reference intervals for thyroid hormones. Finally, the effect of age on the reference intervals for thyroid hormones used a sample size below the recommended minimum of 120 referents for each age category which could bias the results. In conclusions, the developed reference interval limit for TSH, and T3 for the Taita-Taveta County, Kenya population are both gender and age independent, while those of T4 are age dependent for females and gender dependent for age 70-95 years. However, these developed reference interval limits for TSH, T4 and T3 are different from those indicated in the manufacturers' inserts reagent kits, and those developed and reported previously in medical literature in their lower and upper limits using different referent individuals and analytical methods of different parts of the world. These developed reference intervals for thyroid hormones can therefore be adopted for use in the Department of Clinical Chemistry, Moi Subcounty Hospital, Voi, Taita-Taveta County, Kenya and other hospitals within the County.

References

- 1. Ali NI, Alamoudi AO, Adam I. Reference intervals of thyroid hormones in a previously iodine-deficient area in Darfur, Sudan. Therapeutic Advances in Endocrinology and Metabolism. 2018;9(9):293-297.
- 2. Barbesino G. Thyroid function changes in the elderly and their relationship to cardiovascular health: A Mini-Review. Gerontology. 2019;65:1-8.
- 3. Bensenor IM, Olmos RD, Lotufo PA. Hypothyroidism in the elderly: diagnosis and management. Clinical Interventions in Aging. 2012;7:97-111.
- 4. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews. 2008;29:76-131.
- 5. Brent GA. Maternal thyroid function: interpretation of thyroid function tests in pregnancy. Clinical Obstetrics and Gynecology. 1997;40(1):3-15.
- Çavuşoğlu AC, Bilgili S, Erkizan O, Arican H, Karaca B. Thyroid hormone reference intervals and the prevalence of thyroid antibodies. Turkish Journal of Medical Sciences. 2010;40 (4):665-672.
- 7. Gesing A, Lewiński A, Karbownik-Lewińska M. The thyroid gland and the process of aging; what is new? Thyroid Research, 2012;5:16
- 8. Hickman PE, Koerbin G, Simpson A, Potter JM, Hughes DG, Abhayaratna WP, *et al.* Using a thyroid disease-free population to define the reference interval for TSH and free T4 on the Abbott Architect analyser. Clinical Endocrinology. 2017;86:108-112.
- 9. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, *et al.* Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition

- Examination Survey (NHANES III). The Journal of Clinical Endocrinology and Metabolism. 2002;87(2):489-499.
- Horowitz GL, Altaie S, Boyd JC, Ceriotti F, Garg U, Horn P, Pesce A, Sine HE. Clinical and Laboratory Standards Institute (CLSI). Defining, establishing, and verifying reference intervals in the Clinical Laboratory, 3rd Edition. CLSI document EP28-A3c 2008. http://www.thyroidresearchjournal.com/content/5/1/1 http://www.thyroidresearchjournal.com/content/5/1/16
- 11. Kratz A, Ferraro M, Sluss PM. Lewandrowski KB. Laboratory reference values. New England Journal of Medicine. 2004;351(15):1548-1563.
- 12. Kratzsch J, Fiedler GM, Leichtle A, Brügel M, Buchbinder S, Otto L, *et al.* New reference intervals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry Criteria and Regular Ultrasonography of the thyroid. Clinical Chemistry. 2005;51(8):1480-1486.
- 13. Li ZZ, Yu BZ, Wang JL, Yang Q, Ming J, Tang YR. Reference intervals for thyroid-stimulating hormone and thyroid hormones using the access TSH 3rd IS method in China. Journal of Clinical and Laboratory Analysis. 2020;34:e23179. https://doi.org/10.1002/jcla.23197
- 14. Lockitch G. Handbook of Diagnostic Biochemistry and Hematology in Normal Pregnancy. Boca Raton, CRC, 1993.
- Mirjanic-Azaric B, Avram S, Stojakovic-Jelisavac T, Stojanovic D, Petkovic M, Bogavac-Stanojevic N, et al. Direct estimation of reference intervals for thyroid parameters in the Republic of Srpska. Journal of Medical Biochemistry. 2017;36:137-144.
- Musa IR, Ali NI, Elseed SA, Osman OE, Adam I. Reference intervals of thyroid hormones in Khartoum, Sudan. BMC Research Notes. 2018;11:729. https://doi.org/10.1186/s13104-018-3840-5
- 17. Omuse G, Kassim A, Kiigu F, Hussain SR, Limbe M. Reference intervals for thyroid stimulating hormone and free thyroxine derived from neonates undergoing routine screening for congenital hypothyroidism at a university teaching hospital in Nairobi, Kenya: a cross sectional study. BMC Endocrine Disorders. 2016;16(1):23. Doi: 10.1186/s12902-016-0107-9
- 18. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, *et al.* American thyroid association taskforce on thyroid disease during pregnancy and postpartum. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21(10):1081-1125.
- 19. Suzuki S, Nishio SI, Takeda T, Komatsu M. Gender-specific regulation of response to thyroid hormone in aging. Thyroid Research. 2012;5:1
- Tarnoki AD, Tarnoki DL, Speer G, Littvay L, Bata P, Garami Z, et al. Genetic and environmental influence on thyroid gland volume and thickness of thyroid isthmus: a twin study. Archives of Endocrinology and Metabolism. 2015;59(6):487-494.
- 21. Viduetsky A, Herrejon CL. Sonographic evaluation of thyroid size: A review of important measurement parameters. Journal of Diagnostic Medical Sonography. 2019;35(3):206-210.

- 22. Völzke H, Alte D, Kohlmann T, Lüdemann J, Nauck M, John U, *et al.* Reference intervals of serum thyroid function tests in a previously iodine-deficient area. Thyroid. 2005;15(3):279-285.
- 23. Wang Y, Zhang YX, Zhou YL, Xia J. Establishment of reference intervals for serum thyroid-stmulaing hormone, free and total thyroxine, and free and total triiodothyronine for the Beckman Coulter DxI- 800 analyzers by indirect method using data obtained from Chinese population in Zhejiang Province, China. Journal of Clinical and Laboratory Analysis. 2017;31:e22069 https://doi.org/10.1002/jcla.22069
- 24. Yeap BB, Manning L, Chubb SAP, Hankey GJ, Golledge J, Almeida OP, *et al.* Reference ranges for thyroid-stimulating hormone and free thyroxine in older men: Results from the health in men study. Journals of Gerontology: Medical Sciences. 2017;72(3):444-449.